Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
FLOWPHYSIX ANNOUNCES STRATEGIC PARTNERSHIP WITH 3COMMA FOR INTERNATIONAL…
3comma Managing Partner and former Vice President of International at Penumbra, Inc., Marc Paris believes the FLOWRUNNER System will make an immediate impact in the peripheral thrombectomy segment. "We can rapidly activate our established international commercial infrastructure to accelerate adoption of the FLOWRUNNER system. We are confident that FlowPhysix will be the next major disruptor in the global thrombectomy market and we are excited to be part of this endeavor," Paris said…
PR Newswire
11/09/2024
IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors
Mr. Arbel retired as Deputy CEO from Leumi, Israel's largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business. Mr. Arbel retired as Deputy CEO...
PR Newswire
11/09/2024
Trading by management and close relations of management
Please read the full announcement in PDFAttachment 2024_35_Trading_By_Management
Nasdaq GlobeNewswire
11/09/2024
IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative…
Article highlights preclinical findings demonstrating ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity Data show superior killing potency of multiple myeloma tumor cells by ISB 2001 when compared to several approved bispecific therapies and combination of therapiesNEW YORK, Sept.11, 2024(GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage...
Nasdaq GlobeNewswire
11/09/2024
TCI Revolutionizes Weight Management with Breakthrough GLP-1 Innovation
The Science Behind TCI's GLP-1 Formula The Science Behind TCI's GLP-1 Formula TCI leverages its proprietary Bio-Resource Data Mining technology, an AI-powered system that autonomously identifies potent natural compounds. Backed by in-vitro studies and human trials, TCI's GLP-1 formula has proven to be a game-changer in the health and wellness sector. The formula stimulates natural GLP-1 secretion, enhances fat metabolism, stabilizes blood glucose, and induces white fat browning—making it an...
PR Newswire
11/09/2024
Nomination Committee of AB SKF for the Annual General Meeting 2025
Marcus Wallenberg, FAM Philip Ahlgren, Cevian CapitalAnders Algotsson, AFA FörsäkringAnders Jonsson, Skandia, andHans Stråberg, Chair of the Board Marcus Wallenberg, FAM Philip Ahlgren, Cevian Capital Anders Algotsson, AFA FörsäkringAnders Jonsson, Skandia, and Hans Stråberg, Chair of the Board The Annual General Meeting of AB SKF will be held inGothenburgon Tuesday,1 April 2025. Shareholders who wish to submit proposals to the Nomination Committee, may contact the Chair of...
PR Newswire
11/09/2024
Inside information: Orion upgrades full-year outlook for 2024
ORION CORPORATIONSTOCK EXCHANGE RELEASE – INSIDE INFORMATION 11 SEPTEMBER 2024 at 09:30 EEST Inside information: Orion upgrades full-year outlook for 2024Orion Corporation upgrades the full-year outlook for 2024 both for the part regarding net sales and operating profit. Orion's product sales and royalty income has continued to grow faster than expected during the second half of 2024 and this good development is anticipated to continue during the remainder of the year...
Nasdaq GlobeNewswire
11/09/2024
EQT Life Sciences leads EUR 93 million oversubscribed Series A round in PanTera…
Targeted Alpha Therapy is a promising new cancer treatment approach that enables safe and effective delivery of radiation to the cancer cells by radioisotopes that emit highly energetic alpha particles. The radiation effect of the alpha particle is more localized compared to other approaches and as such can destroy the cancer cells to which it is attached without harming surrounding healthy tissue. The most promising alpha emitter for this approach is 225Ac. As a result, demand for 225Ac is…
PR Newswire
11/09/2024
Press Release: Dupixent phase 3 study confirms significant improvements in itch…
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placeboMore than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistaminesData...
Nasdaq GlobeNewswire
11/09/2024
IBA's joint venture PanTera secures EUR 93 million in oversubscribed Series A…
Louvain-la-Neuve, Belgium, September 11, 2024 – IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, is pleased to share the below press release from its joint venture PanTera, which is focussed on the production of actinium-225, a novel radioisotope used in a new class of targeted treatments for cancer. The Series A financing values PanTera at about EUR 280 million post money. Prior to the funding round, IBA had a 47.8% shareholding in PanTera and...
Nasdaq GlobeNewswire
11/09/2024
Press Release: Dupixent is the first and only biologic to achieve significant…
Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal studyStudy met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placeboDupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease If approved, Dupixent...
Nasdaq GlobeNewswire
11/09/2024
'Highly Accurate': Telix's Phase III ZIRCON Trial for Kidney Cancer Imaging…
Authors explain that small masses in the kidney are increasingly being detected incidentally when patients undergo abdominal imaging, often for other health conditions, contributing to "an era of gross overtreatment". Diagnosis and treatment are limited by current imaging techniques, and renal mass biopsy is invasive, which can often lead to complications. Up to 30% of patients undergo unnecessary surgery, removing masses that are later determined to be benign[4]. If confirmed…
PR Newswire
11/09/2024
Global Respiratory Monitoring Devices Market to Register Sustainable Growth at a…
Key Takeaways from the Respiratory Monitoring Devices Market Report Key Takeaways from the Respiratory Monitoring Devices Market Report To read more about the latest highlights related to the respiratory monitoring devices market, get a snapshot of the key highlights entailed in theGlobal Respiratory Monitoring Devices Market Report Respiratory Monitoring Devices Overview Respiratory monitoring devices play a critical role in assessing and managing patients' respiratory...
PR Newswire
10/09/2024
BTK Inhibitors Market to Observe Stunning Growth by 2034 | DelveInsight
Key Takeaways from the BTK Inhibitors Market Report Key Takeaways from the BTK Inhibitors Market Report Discover which therapies are expected to grab the BTK inhibitors market share @BTK Inhibitors Market Report BTK Inhibitors Market Dynamics The BTK inhibitors market has experienced significant dynamics driven by advancements in oncology and autoimmune disease treatments. One of the primary drivers of the BTK inhibitors market is theincreasing incidence of cancerssuch...
PR Newswire
10/09/2024
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; September 10, 2024 –Genmab A/S(Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:4,623 shares at DKK 1,025.00, 3,656 shares at DKK 1,032.00, 561 shares at DKK 1,050.00, 1,645...
Nasdaq GlobeNewswire
10/09/2024
Sectra's Annual General Meeting 2024--resolution passed on share redemption…
It will be possible to trade in Class B redemption shares (ISIN: SE…) on Nasdaq Stockholm. It will be possible to trade in Class B redemption shares (ISIN: SE…) on Nasdaq Stockholm. Timetable for the redemption procedure: For information about the redemption procedure, visithttps://investor.sectra.com/redemption2024. Performance based incentive program LTIP 2024The AGM resolved on a long-term performance-based incentive program, LTIP 2024, which is to apply to a maximum of...
PR Newswire
10/09/2024
Bioinformatics Market to Reach $31.71 Billion by 2031, Driven by Growing…
Download FREE PDF Brochure Of Bioinformatics Market:- https://www.meticulousresearch.com/download-sample-report/cp_id=5731 Download FREE PDF Brochure Of Bioinformatics Market:- https://www.meticulousresearch.com/download-sample-report/cp_id=5731 The growth of the biotechnology & pharmaceutical industries, initiatives supporting genomics research, and the rising need to develop novel drugs/drug molecules are key factors driving the growth of the bioinformatics market. However, the...
PR Newswire
10/09/2024
Mosquito Repellents Market Surges to USD 9.0 Billion by 2030, Propelled by 5.6%…
Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=494144 Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=494144 Browse in-depth TOC onMosquito Repellents Market 202 - Pages 126 – Tables 37 – Figures Scope of The Report Global Mosquito Repellents Market Overview Rising Health Concerns and Disease Prevention As global health awareness grows, so does the focus on preventing mosquito-borne...
PR Newswire
10/09/2024
Breathing Circuits Market to Hit USD 2.16 Billion by 2029 with 6.5% CAGR |…
Browse in-depth TOC on "Breathing Circuits Market" Browse in-depth TOC on "Breathing Circuits Market" 289 - Tables 59 - Figures 281 - Pages Dominance of Disposable Breathing Circuits The market is categorized by usage into disposable and reusable breathing circuits. In 2023, disposable breathing circuits led the market share due to growing concerns over patient safety and efforts to minimize healthcare-associated infections. These single-use circuits help prevent...
PR Newswire
10/09/2024
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to…
Liquid biopsy testing offers a complementary alternative to solid tumor testing, which is not always feasible due to insufficient tissue, low quality tissue, or the invasiveness of the procedure. The testing works by isolating cell-free DNA (cfDNA) from blood plasma to uncover circulating tumor DNA (ctDNA). Isolating these DNA samples from a simple blood draw is less invasive than a traditional biopsy, helping to simplify patient monitoring and more quickly guide clinical decision-making. ...
PR Newswire
10/09/2024
Preclinical CRO Market Expands at 6.5% CAGR, Driven by Advances in Drug…
Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=360758 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=360758 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Preclinical CRO Market Overview Geographic Dominance : Geographic dominance in the Preclinical CRO market is notably pronounced inNorth America,Europe, andAsia-Pacific.North America, particularlythe United States...
PR Newswire
10/09/2024
Roche opens Pharma Research and Development Center in Basel to accelerate…
Switzerland's most innovative research and development center underscores Roche's long-term investment in scientific advancement to meet patient needsThe new center will simplify and increase collaboration thereby accelerating scientific innovationGuy Parmelin, Federal Counsel and Head of the Federal Department of Economic Affairs, Education and Research (EAER) will attend the center's inauguration Basel, 10 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today...
Nasdaq GlobeNewswire
10/09/2024
LifeSpan Vision Ventures Invests in Remedium Bio
The funding will be used to advance the company's lead candidate, RMD-1202, towards Phase 1 studies. RMD-1202 delivers a GLP-1 receptor agonist and demonstrates weight loss, glycemic control, and insulin response superior to daily GLP-1 protein injections - with a potentially increased safety and tolerability profile. The platform can deliver a broad range of proteins, from peptides to antibodies and Remedium is developing additional therapies across musculoskeletal, immunology, and neurology…
PR Newswire
10/09/2024
Virbac : Declaration of the number of shares and voting rights 08/2024
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsAugust, 31 20248 458 000Gross total of voting rights :...
Nasdaq GlobeNewswire
10/09/2024
Altri Comunicati
